Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2211425 | 0.98 | SLC1A1 (0.54) | SLC1A1TAAR1IDO1AGXTMAOB | |
| SCHEMBL29410132 | 0.83 | PNMT (0.60) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL14478266 | 0.83 | PNMT (0.60) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL2561950 | 0.83 | PNMT (0.60) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL1530031 | 0.83 | PNMT (0.60) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL23886297 | 0.83 | TAAR1 (0.52) | SLC1A1TAAR1IDO1AGXTMAOB | |
| SCHEMBL12706104 | 0.82 | SLC1A1 (0.51) | SLC1A1TAAR1IDO1AGXT | |
| Hydrochloric Acid SCHEMBL6819301 | 0.82 | PNMT (0.58) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL3282231 | 0.81 | SLC1A1 (0.54) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL7458228 | 0.80 | TAAR1 (0.55) | SLC1A1TAAR1IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5908960-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| WO-2025089147-A1 | HERBICIDAL COMPOSITION | 株式会社エス・ディー・エス バイオテック | 2025-05-01 | — | — | WO | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| EP-2121642-B1 | 4-HYDR0XY-2-0X0-2, 3 -DIHYDRO- 1, 3-BENZOTHIAZOL- 7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249200-A1 | Novel Compounds 569 | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-7700782-B2 | Compounds 569 | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20100022491-A1 | 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| EP-2121642-A1 | 4-HYDR0XY-2-0X0-2, 3 -DIHYDRO- 1, 3-BENZOTHIAZOL- 7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080207698-A1 | Novel Compounds 569 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008075026-A1 | 4-HYDR0XY-2-0X0-2, 3 -DIHYDRO- 1, 3-BENZOTHIAZOL- 7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-5908960-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207698-A1 | Novel Compounds 569 | RB1, CNKSR1, CDK9 | SLC1A1 4691/4885TAAR1 1241/4885IDO1 3475/4885 |
| US-20100022491-A1 | 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ADRB2, ADRB1, ADRA2C | SLC1A1 1657/4885TAAR1 96/4885IDO1 4179/4885 |
| US-20100249200-A1 | Novel Compounds 569 | RB1, CNKSR1, CDK9 | SLC1A1 4691/4885TAAR1 1241/4885IDO1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.